EMA Recommends Treatment for Maple Syrup Urine Disease
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an exceptional circumstances positive opinion for Maapliv, a solution of amino acids intended for the treatment of maple syrup urine disease (MSUD) in patients presenting with an acute decompensation episode from birth and who are not eligible for …
Read More
0
